,2 In addition, wide-spread marketing of the weight loss benefits of these drugs has spurred media attention highlighting differences in use and access between over-resourced and under-resourced populations.3, 4, 5 Previous research studies evaluating patients with T2DM found racial, ethnic, and socioeconomic disparities in prescribing patterns of GLP-1 RAs.6 The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.